Mersana Therapeutics Shares Are Trading Lower. The Company Announced Initial Clinical Data From the Phase 1 Dose Escalation and Backfill Cohorts for Emiltatug Ledadotin.
Mersana Therapeutics Shares Are Trading Lower. The Company Announced Initial Clinical Data From the Phase 1 Dose Escalation and Backfill Cohorts for Emiltatug Ledadotin.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.